From: Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project
Diagnostic phase | |
% patients diagnosed at different hospital | |
% patients with pre-treatment MRI, pelvic ultrasound, thoraco–abdominal CT | |
% patients with TNM, MRI staging | |
Time between biopsy and first visit at RO | |
Time between first visit at RO department and beginning of radiotherapy | |
% patients evaluated pre-treatment in RO department clinical session | |
% patients presented to Multidisciplinary Tumour Board (MTB) | |
Treatment phase | |
% patients included in clinical trial | |
% patients Long Course Radiotherapy (LCRT) | |
% patients Short Course Radiotherapy (SCRT) | |
% patients with 3DCRT, VMAT, IMRT | |
% patients with simultaneous-integrated boost (SIB) | |
% patients immobilized | |
% patients completing treatment in the prescribed time | |
% patients with treatment interruption of EBRT, due to patient-related reasons, due to centre-related reasons, with dose compensation | |
Overall treatment time (time between first and last day of treatment) | |
% patients presented to the second MTB, to the MTB after surgery | |
% patients with restaging MRI, US pelvic, TNM | |
Pathology report | |
% patients with post-surgery ypT, ypN staging | |
% patients with adjuvant chemotherapy | |
Side effects | |
Acute (< 6 months) and chronic (≥ 6 months) adverse effects ≥ grade 3 | |
% patients with rectitis, cystitis-urethritis, neutropenia, diarrhea | |
Patient follow up | |
Regular follow-up (≥ 2 visits per annum) after the treatment | |
% patients with relapse, mortality |